Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 14/20 | 0.36 |
| ▸ | PTAFR | P25105 | 3/20 | 0.35 |
| ▸ | BRD2 | P25440 | 5/20 | 0.33 |
| ▸ | BRD3 | Q15059 | 4/20 | 0.33 |
| ▸ | BRDT | Q58F21 | 4/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | DNER | Q8NFT8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8325567 | 0.91 | OPRK1 (0.46) | OPRK1PDE4DBRD4PTAFRBRD2 | |
| SCHEMBL8319632 | 0.91 | OPRK1 (0.43) | OPRK1PDE4DBRD4PTAFR | |
| SCHEMBL8318026 | 0.89 | OPRK1 (0.44) | OPRK1PDE4DBRD4PTAFRBRD2 | |
| SCHEMBL8319731 | 0.89 | OPRK1 (0.42) | OPRK1PDE4DBRD4PTAFRBRD2 | |
| SCHEMBL8319634 | 0.88 | OPRK1 (0.42) | OPRK1PDE4DBRD4PTAFRBRD2 | |
| SCHEMBL8316021 | 0.87 | OPRK1 (0.41) | OPRK1PDE4DBRD4PTAFRBRDT | |
| SCHEMBL21847137 | 0.84 | OPRK1 (0.41) | OPRK1PDE4DBRD4PTAFR | |
| SCHEMBL21847113 | 0.82 | BRD4 (0.37) | BRD4BRD2BRD3BRDTTP53 | |
| SCHEMBL8319205 | 0.82 | OPRK1 (0.43) | OPRK1PDE4DBRD4PTAFR | |
| SCHEMBL8317069 | 0.81 | BRD4 (0.41) | OPRK1PDE4DBRD4PTAFRBRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11186588-B2 | 6H-thieno[2,3-e][1,2,4]triazolo[3,4-c][1,2,4]triazepine derivative | AYUMI PHARMACEUTICAL CORPORATION (JP) | 2021-11-30 | — | — | US | claimed |
| US-20210130367-A1 | 6H-THIENO[2,3-e][1,2,4]TRIAZOLO[3,4-c][1,2,4]TRIAZEPINE DERIVATIVE | AYUMI PHARMACEUTICAL CORPORATION (JP) | 2021-05-06 | — | — | US | claimed |
| EP-3640253-A1 | 6H-THIENO[2,3-E][1,2,4]TRIAZOLO[3,4-C][1,2,4]TRIAZEPINE DERIVATIVE | AYUMI Pharmaceutical Corporation (JP) | 2020-04-22 | — | — | EP | claimed |
| EP-0934940-A1 | CYTOKINE PRODUCTION INHIBITORS, TRIAZEPINE COMPOUNDS, AND INTERMEDIATES THEREOF | Japan Tobacco Inc. (JP) | 1999-08-11 | — | — | EP | claimed |
| US-5807850-A | Therapeutic agent for osteoporosis and triazepine compound | JAPAN TOBACCO, INC. (JP) | 1998-09-15 | — | — | US | claimed |
| EP-0792880-A1 | OSTEOPOROSIS REMEDY AND TRIAZEPINE COMPOUND | Japan Tobacco Inc. (JP) | 1997-09-03 | — | — | EP | claimed |
| US-11186588-B2 | 6H-thieno[2,3-e][1,2,4]triazolo[3,4-c][1,2,4]triazepine derivative | AYUMI PHARMACEUTICAL CORPORATION (JP) | 2021-11-30 | — | — | US | disclosed |
| US-20210130367-A1 | 6H-THIENO[2,3-e][1,2,4]TRIAZOLO[3,4-c][1,2,4]TRIAZEPINE DERIVATIVE | AYUMI PHARMACEUTICAL CORPORATION (JP) | 2021-05-06 | — | — | US | disclosed |
| EP-3640253-A1 | 6H-THIENO[2,3-E][1,2,4]TRIAZOLO[3,4-C][1,2,4]TRIAZEPINE DERIVATIVE | AYUMI Pharmaceutical Corporation (JP) | 2020-04-22 | — | — | EP | disclosed |
| CN-1227555-A | Cytokine production inhibitors triazepine compounds, and intermediates thereof | JAPAN TOBACCO INC (JP) | 1999-09-01 | — | — | CN | disclosed |
| EP-0934940-A1 | CYTOKINE PRODUCTION INHIBITORS, TRIAZEPINE COMPOUNDS, AND INTERMEDIATES THEREOF | Japan Tobacco Inc. (JP) | 1999-08-11 | — | — | EP | disclosed |
| US-5807850-A | Therapeutic agent for osteoporosis and triazepine compound | JAPAN TOBACCO, INC. (JP) | 1998-09-15 | — | — | US | disclosed |
| CN-1171788-A | Therapeutic agent for osteoporosis and triaza * compound | JAPAN TOBACCO INC (JP) | 1998-01-28 | — | — | CN | disclosed |
| EP-0792880-A1 | OSTEOPOROSIS REMEDY AND TRIAZEPINE COMPOUND | Japan Tobacco Inc. (JP) | 1997-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130367-A1 | 6H-THIENO[2,3-e][1,2,4]TRIAZOLO[3,4-c][1,2,4]TRIAZEPINE DERIVATIVE | BRD4, BRD3, BRD2 | OPRK1 1119/4885PDE4D 3651/4885BRD4 1/4885 |
| US-11186588-B2 | 6H-thieno[2,3-e][1,2,4]triazolo[3,4-c][1,2,4]triazepine derivative | BRD4, BRD3, BRD2 | OPRK1 1119/4885PDE4D 3651/4885BRD4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.